# SL Science Holding Ltd > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/SL Science Holding Ltd). ## Overview SL Science Holding Ltd is a U.S.-listed biotechnology and biological products company based in Taipei, Taiwan, operating through its SL Bio business. It develops and commercializes exosome-based skincare and haircare products and is also building a pipeline around licensed cell therapy and related life-science technologies. ## Products & services • Exosome-based skincare products • Exosome-based haircare products • Corporate distribution of branded exosome products • Licensed CD-19 Armed-T cell therapy rights • Licensed gamma delta T cell therapy programs - **Exosome consumer products** (55%) — Skincare and haircare products sold under SL Science's branded exosome portfolio. - **Corporate distribution** (20%) — Wholesale and distribution sales of exosome products to corporate customers and partners. - **Licensed cell therapy programs** (20%) — Development rights and related services tied to CD-19 Armed-T and GDT cell therapy assets. - **Research and technical services** (5%) — Support activities, documentation preparation, and technical services linked to licensed programs. - Exosome-based skincare products - Exosome-based haircare products - Corporate distribution of branded exosome products - Licensed CD-19 Armed-T cell therapy rights - Licensed gamma delta T cell therapy programs ## Customers The company sells mainly to consumers through skincare and haircare channels, and to corporate customers that distribute or market its exosome products. It also works with licensing and development partners in cell therapy, where counterparties fund or milestone-support specific technologies. Demand is tied to premium beauty, regenerative health, and biopharma development use cases. - **Consumer beauty buyers** (primary) — Buy exosome skincare and haircare products for anti-aging and regenerative benefits. - **Corporate distributors** (primary) — Purchase branded products for resale and market coverage in Asia. - **Biotech licensing partners** (secondary) — Enter licensing and collaboration arrangements around Armed-T and GDT assets. - **Professional/clinical customers** (secondary) — Use technical support and product training tied to corporate distribution or development programs. - Consumers buying exosome skincare and haircare products - Corporate customers distributing branded products in Asia - Commercial partners marketing products under distribution rights - Licensing counterparties in cell therapy development - Biotech collaborators needing IP, validation, or technical support ## Geography The business is centered in Taiwan, where the company is headquartered and where exosome sales to corporate customers have been disclosed. It also uses distribution arrangements to promote branded products across Asia, making regional channel access an important part of the model. The company is incorporated in the United States and accesses U.S. capital markets, while its commercial footprint remains Asia-focused. - Headquartered in Taipei, Taiwan - Corporate customers and distribution activity disclosed in Taiwan - Products are promoted through Asia-focused distribution rights - U.S. listing provides capital-market access - Commercial and supply-chain exposure is concentrated in Asia ## Strategy The company is building a two-track model: branded exosome products for consumer and corporate channels, and licensed cell-therapy assets for longer-dated value creation. Its strategy centers on expanding Asian distribution, strengthening partner-led commercialization, and advancing regulated therapeutic programs toward clinical milestones. Scaling production, channel reach, and licensed intellectual property are central to its competitive position. - **Expand corporate distribution in Asia** (short-term) — Broader channel coverage can lift product reach and reduce reliance on retail sales. - **Advance cell-therapy development programs** (medium-term) — Clinical progress can unlock licensing value and future commercialization options. - **Secure and manage licensing relationships** (medium-term) — Future revenues depend on the duration and performance of licensed technology agreements. - Expand exosome sales from retail into corporate channels - Use Asian distribution partnerships to widen market access - Advance Armed-T and GDT programs through FDA steps - Monetize licensing IP through milestone-based agreements - Build production and technical capacity for future scale ## Risks The business depends on a single exosome supplier in Taiwan, licensed technology partners, and regulatory outcomes for its therapeutic pipeline. It also faces execution risk from clinical development, milestone obligations, and the need to scale specialized manufacturing and technical capabilities. As a biotech and biological-products business, commercialization timing, product acceptance, and reimbursement or regulatory clearance can materially affect future performance. - **Single-supplier concentration** [high] — Exosome product costs and availability depend on one supplier in Taiwan, limiting bargaining power and resilience. - **Regulatory approval uncertainty** [high] — The company has no FDA-approved products and therapeutic programs must clear nonclinical and IND hurdles. - **License milestone payments** [high] — Future cash outflows depend on achievement of development milestones under licensing agreements. - **Clinical and development failure** [high] — Early-stage cell therapy assets may not produce successful data or regulatory progress. - Single-supplier dependence for exosome products - FDA and regulatory approval risk for therapeutic programs - Milestone obligations on licenses can create cash commitments - Partner dependence for commercialization and IP access - Clinical development risk in cell-therapy programs ## Accounting Revenue recognition likely depends on product sales, distribution arrangements, and licensing services, where timing can vary by shipment, delivery, or milestone achievement. The company also has significant judgment in accounting for license obligations, contingent milestone payments, and related research or development commitments. As a development-stage biotech, impairment, going-concern evaluation, and fair-value judgments can also affect reported results and disclosures. - **Revenue recognition** — Affects quarterly revenue timing and comparability - **Milestone payments** — Creates estimate-based liabilities and future cash outflows - **Going concern** — Important for valuation, liquidity assessment, and disclosure risk - **Research and development commitments** — Affects expenses, liabilities, and cash planning - Product sales timing affects exosome revenue recognition - Distribution and licensing terms may include variable consideration - Milestone obligations create contingent liabilities and estimates - Research and license commitments affect accruals and disclosures - Going-concern and impairment judgments are important for analysis --- *Last updated: 2026-09-28T12:13:56.803788+00:00*